MAIA Biotechnology, Inc. SEC filings MAIA
MAIA Biotechnology, Inc. has 503 filings in SEC EDGAR's recent list, going back to Oct 15, 2021. Its latest annual report, Form ARS, was filed on Apr 7, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 6, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 19, 2026 | — |
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEFA14A | Additional proxy material | Apr 7, 2026 | — |
| DEF 14A | Proxy statement | Apr 7, 2026 | May 21, 2026 |
| DEFA14A | Additional proxy material | Apr 8, 2025 | — |
| DEF 14A | Proxy statement | Apr 8, 2025 | May 22, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 28, 2025 | Mar 28, 2025 |
| DEF 14A | Proxy statement | Apr 16, 2024 | May 24, 2024 |
| DEF 14A | Proxy statement | Apr 19, 2023 | May 25, 2023 |
Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MAIA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1878313
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.